Objective: Early and midterm outcomes of the Prospective Aneurysm Trial: High Angle Aorfix Bifurcated Stent Graft (PYTHAGORAS) trial in patients with highly angulated aortic necks ($60 degrees) have already been published and shown comparable outcomes to other endografts in normal anatomy. Herein, we present the long-term outcomes of the PYTHAGORAS trial of Aorfix (Lombard Medical, Irvine, Calif) for patients with highly angulated aortic neck anatomy.
Endovascular aneurysm repair (EVAR) is associated with significantly lower morbidity and mortality compared with open repair and thus has become the preferred means by which to treat abdominal aortic aneurysms (AAAs). [1] [2] [3] [4] However, there are a number of anatomic factors that limit the applicability of EVAR to some patients. 5 Severe infrarenal aortic neck angulation (ie, $60-degree angulation between the infrarenal aortic neck and the longitudinal axis of the aneurysm) is one major limitation to the use of EVAR. Increasing aortic neck angulation has been shown to increase perigraft endoleak flow, thereby leading to poor seal and graft separation. 6, 7 Consistent with this notion, severe aortic neck angulation has been associated with worse outcomes after EVAR in multiple prior studies. 8 In a prospective study of 81 EVAR repairs by Sternbergh et al, patients with severely angulated aortic necks had a 70% risk of experiencing one or more adverse events (including death within 30 days, acute conversion to open repair, aneurysm expansion, device migration, and type I endoleak) compared with a 17% risk in patients with mild (<40-degree) aortic neck angulation. 9 Similarly, data from 5183 EVAR patients enrolled in the EUROSTAR Registry demonstrated that severe infrarenal aortic neck angulation is associated with a significantly higher risk of proximal aneurysm neck dilation, type I endoleak, and secondary interventions. 10 As a result, most manufacturers exclude highly angulated aortic necks from their aortic stent graft instructions for use (IFU).
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The Aorfix bifurcated aortic stent graft (Lombard Medical, Irvine, Calif) was designed to address this problem. Consisting of flexible nitinol rings covered in polyester, the Aorfix is a transrenal endograft that can be used in patients with highly angulated aortic neck anatomy because the body of the graft is more flexible than most Z stent designs. 12 In 2006, Albertini et al first described promising outcomes using the Aorfix stent graft in 29 patients treated in Europe, 23 of whom had severely angulated aortic necks. 13 In 2011, Weale et al subsequently published reasonable safety outcomes and good short-term success among 30 patients with severe neck angulation (60-90 degrees) treated with the Aorfix as part of the Aorfix Bifurcated Safety and Performance Trial: Phase II, Angulated Vessels (ARBITER 2) trial in the United Kingdom. 14 Both of these studies were limited to describing technical success and short-term (#6-month) outcomes. 13, 14 More recently, the Prospective Aneurysm Trial: High Angle Aorfix Bifurcated Stent Graft (PYTHAGORAS trial) was initiated. PYTHAGORAS is a multicenter U.S. trial designed to evaluate the safety and effectiveness of Aorfix endograft for the treatment of highly angulated aortic necks or tortuous aortoiliac anatomy. 15 The early and midterm (2-year) outcomes of the PYTHAGORAS trial have been previously published and demonstrate outcomes with use of the Aorfix that are comparable to those with other endografts in normal anatomy. 16 On the basis of these initial results, the Aorfix was approved by the Food and Drug Administration (FDA) for 0-to 90-degree neck angles and remains the only on-label alternative to open repair for patients with highly angulated aortic necks. 17 However, the long-term outcomes of this stent graft were unknown. Herein, we report the long-term (5-year) outcomes of the PYTHAGORAS trial using the Aorfix for endovascular repair of AAA in patients with both standard-angle and highly angulated aortic necks.
METHODS
PYTHAGORAS trial. The PYTHAGORAS study is a multicenter, nonrandomized regulatory study approved by the U.S. FDA to evaluate the safety and effectiveness of the Lombard Medical Aorfix endograft for the treatment of abdominal aortic, aortoiliac, and common iliac aneurysms with anatomies including angled aorta, angled aneurysmal body, or both, between 0 and 90 degrees. 15 It is the first clinical trial designed to test the use of EVAR for highly angulated ($60-degree) aortic necks.
Participants were treated between April 28, 2006 , and September 30, 2011. The indication for enrollment was highly angulated aortic neck anatomy as determined by the on-site investigator. Anatomic exclusion criteria (as measured by that investigator) included (1) insufficient length of proximal aneurysm neck (ie, <15 mm of centerline length from the lowest renal artery or <20 mm of centerline length from superior mesenteric artery to the top of the aneurysm sac); (2) distal landing zone <15 mm; and (3) aortic neck or iliac artery landing zone diameter outside the device range indicated in the IFU. A detailed description of the study design has been previously published. 16 The study protocol and informed consent were approved by the Institutional Review Boards at all participating institutions (N ¼ 45). All patients were required to complete informed consent before participation. An independent data monitoring committee was established to ensure overall safety of the study.
Device. The Aorfix endograft is a bifurcated aortic stent graft that was designed to treat AAAs with highly angulated necks. It employs polyester graft material surrounded by nitinol rings, rather than Z stents, that allow the device to conform to the angulation of the native aorta without collapsing. There are four pairs of hooks, proximal on the graft, that are attached within an 8-mm primary sealing ring to allow transrenal fixation. When implanted, the stent graft rings are deformed to have a saddle or "fishmouth" shape. This shape allows the stent graft to be placed transrenally, with the fishmouth troughs aligned with the renal arteries juxtarenally and the fishmouth peak extending suprarenally. A complete description of the device design has been detailed in prior publications. 16, 18 Aortic neck angulation. Although individual on-site investigators enrolled patients on the basis of their own measurements, a core laboratory was used to standardize all measurements before analysis. Aortic neck angle measurements were determined by the core laboratory on the basis of preoperative three-dimensional computed tomography (CT) imaging (M2S, West Lebanon, NH) using the method previously illustrated by Chaikof et al 19 and similar to a technique described by van Keulen et al. 20 Patients were divided into two groups for the purposes of this analysis: those with standard aortic neck angulation (<60 degrees) and those with highly angulated aortic necks ($60 degrees).
Follow-up. All patients enrolled in the study were scheduled to undergo follow-up examinations at 1 month, 6 months, and 12 months postoperatively and then annually for a total of 5 years from the index procedure. An abdominal radiograph and CT imaging with contrast enhancement were required for all patients at the 1-month, 12-month, and subsequent annual visits. Duplex ultrasound imaging was used as an adjunct for patients who had recent CT scans performed without contrast enhancement as a means to assess the degree of thrombus present in the neck of the aneurysm. No use was made in the analysis presented here or to the FDA of measurements that were made by ultrasound.
The core laboratory reviewed all postoperative imaging studies (CT scans and abdominal radiographs) to assess all components of the primary efficacy end points, including aneurysm changes, device integrity and position, and presence of endoleaks.
Primary outcome. The original primary study outcome for the PYTHAGORAS trial was the proportion of endografts remaining free from endoleak, migration >10 mm from original position, and fracture at 12 months postoperatively. 15 The short-term (2-year) results reporting the efficacy of the Aorfix for the treatment of highly angled aortic necks have been previously published. 16 The aim of the current study was to compare long-term (5-year) outcomes after EVAR for infrarenal AAA using the Aorfix endograft among patients with highly angulated aortic necks ($60 degrees) vs those with standard aortic necks (<60 degrees).
Statistical methods. The PYTHAGORAS trial enrolled 218 patients. Control groups were followed up for only 12 months and included enrolled open surgical patients (N ¼ 76) as well as a meta-analysis of open control patients from prior U.S. EVAR clinical trials (N ¼ 323). For the purposes of the current study, analyses were limited to patients undergoing EVAR with the Aorfix.
All outcomes were analyzed on an intention-to-treat basis. Descriptive statistics were performed using univariable analyses including mean and standard deviation for continuous variables and frequency and percentage for categorical variables. Comparisons between groups were made using independent samples t-tests for continuous data and Fisher exact tests for categorical data, with significance set at P < .05. Mortality (overall and aneurysm related) and EVAR-specific complications including type I or type III endoleaks, endograft migration >10 mm, barb and stent fracture, and need for secondary intervention were compared between standard and highly angulated neck groups at 5 years using standard statistical methods. Kaplan-Meier survival analyses were also performed to evaluate the freedom from overall mortality, aneurysm-related mortality, aneurysm sac rupture, and reintervention, both for the study cohort overall and between the standard and highly angulated neck groups.
All statistical analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC).
RESULTS
Study cohort. A total of 218 patients were enrolled for an Aorfix procedure, of whom 210 successfully completed the procedure. Graft deployment was unsuccessful in the remaining eight patients because of access issues. All analyses were completed using all 218 Aorfix patients in an intention-to-treat analysis.
The mean age of Aorfix-treated patients was 75.6 6 7.5 years; 29% were female, and 92% were of white race. Nearly all patients (93%; n ¼ 202) had a history of cardiovascular disease, and the majority (87%; n ¼ 190) had a history of tobacco use. A complete overview of the overall study cohort is provided in Table I .
Of the 218 patients treated, there were 67 patients in the <60-degree (standard angle) neck group and 151 patients in the $60-degree (highly angulated) neck group. Patients with highly angulated necks were older (76.3 6 7.2 vs 74.0 6 7.9 years; P ¼ .03), were more frequently female (35% vs 15%; P ¼ .002), and had a higher prevalence of chronic disease (31% vs 15%; P ¼ .02) than patients with standard-angle necks. Tobacco use (83% vs 97%; P ¼ .003) and coagulopathy (0% vs 5%; P ¼ .03) were less common in the highly angled group. A complete summary of patient demographics and baseline medical history is provided in Table I .
Baseline aneurysm characteristics. As expected, the proximal neck angle of the highly angulated neck group was significantly higher than in the standard-angle neck group (83.3 vs 44.7 degrees; P < .001). Within the highly angulated group, 42 patients had aortic neck angulation >90 degrees (range, 91-145 degrees). As measured by the core laboratory, proximal neck length (21.9 6 12.6 mm vs 24.0 6 15.4 mm; P ¼ .28) and the proportion of patients with neck lengths <15 mm (31% vs 31%; P ¼ .97) were similar between groups. Proximal neck diameters, measured at four points, were smaller in the highly angulated group, although the differences reached significance only at the most proximal point measured 1 mm below the distal renal artery (22.2 6 2.7 mm vs 23.4 6 3.4 mm; P < .007) and at the distal end of the aortic neck (24.3 6 3.0 mm vs 25.8 6 3.2 mm; P < .001; Table II ). Aneurysm sac diameter (59.0 6 11.9 mm vs 54.3 6 9.0 mm; P ¼ .005) and sac volume (218 6 108 mL vs 168 6 63 mL; P < .001) were both larger in the highly angulated neck group. Five-year survival. The 5-year freedom from all-cause mortality was 69% (n ¼ 151), including 73% (n ¼ 49) in the standard-angle neck group vs 68% (n ¼ 102) in the highly angulated neck group (P ¼ .43 ; Fig 1, A; Table III ). The 5-year freedom from aneurysm-related mortality was 96% (n ¼ 209), including 95% (n ¼ 143) in the highly angulated neck group vs 99% (n ¼ 66) in the standardangle neck group (P ¼ .44 ; Fig 1, B) .
Five-year EVAR-specific outcomes. At 5 years, 87% of surviving patients were followed up. At 5 years postoperatively, aneurysm sac shrinkage >5 mm in diameter occurred in 61% (n ¼ 52) of patients overall and was similar for the highly angulated vs standard-angle neck groups (60% vs 64%; P ¼ .81). There was a trend toward a higher incidence of sac expansion in the highly angulated neck group (15% vs 4%; P ¼ .27), but this was not statistically significant.
Core laboratory review of annual CTs identified no new type I or type III endoleaks at 2-, 3-, 4-, or 5-year follow-up in either group (Table IV) . The incidence of type II endoleaks was similar between groups at all time points (P $ .47; Table IV ). Stent migration occurred in 3% of highly angulated neck patients vs 4% of standard neck patients and was not significantly different between groups (P ¼ 1.0). There was also no significant association between severely angulated aortic neck angles (>90 degrees) and graft migration (P ¼ 1.0) or type I/III endoleak (P ¼ .43) at any time point. Fracture occurred in 24% of patients, including 23% at the fixation zone (ie, barb fractures) and 1% of the main body stents (Table IV) . Both fixation zone and main body fractures occurred with similar frequency between the highly angulated and standard-angle neck groups (both P ¼ 1.0; Table IV) .
Five-year freedom from sac rupture was 99% in both groups (P ¼ 1.0; Fig 2, A) . Five-year freedom from device-related secondary intervention was 83%, including 80% in the highly angulated neck group vs 88% in the standard-angle neck group (P ¼ .18; Fig 2, B) .
Implant complications. There were a number of implant complications including nine involving renal arteries, six of which were consequent to placing a cuff. Cuff use was particularly common in aneurysms with neck angulation >90 degrees. Seven renal stents were placed, of which three were placed during the index procedure; one of these was placed for concomitant treatment of a diseased renal artery. One superior mesenteric artery was impinged and stented during the index procedure.
During the first postoperative months, two stents were placed to treat compression of the ipsilateral limb at the level of the cannulation gate. Both patients had long and narrow terminal aortas. Poor dilation of the overlap region of three distal extenders caused limb occlusion, and a grossly oversized limb caused a fourth occlusion. We are pleased to report no graft occlusions after the first postoperative year.
DISCUSSION
Whereas prior randomized controlled trials of EVAR vs open AAA repair demonstrate favorable outcomes with EVAR, the inclusion criteria for those studies prohibited enrollment of patients who did not meet the anatomic restrictions of the endograft IFU in place at the time. [1] [2] [3] 21, 22 It is estimated that up to 12% of men and 26% of women may have aortic neck angulation exceeding 60 degrees, making the applicability of existing EVAR stent graft technology "off-label" for approximately a fifth of the U.S. AAA population. 23 The PYTHAGORAS trial was designed to address this limitation. In this multicenter U.S. trial, the safety and efficacy of the flexible Aorfix aortic stent graft were tested among patients with highly angulated aortic necks. 15 Determination of enrollment by on-site investigators allowed a reasonable proportion of enrolled patients to have more challenging aortic neck anatomy than was originally intended by the trial, thereby allowing the results presented here to provide better information about the performance of the Aorfix device in a "real-world" population. Previously, we reported the 2-year outcomes of the Aorfix. 16 At that time, mortality and graft complication rates were similar between patients with standardangle and patients with highly or severely angled aortic necks. However, one of the primary concerns with EVAR is that of long-term follow-up. Patients undergoing standard EVAR require more reinterventions than patients undergoing open AAA repair. 4, 22 Given the concern about obtaining an adequate seal between the stent graft and aortic wall among patients with highly angulated aortic necks, 6 the long-term outcomes of the Aorfix device among patients with standard-angle vs highly angulated aortic necks are particularly important. In the current study, we demonstrate encouraging results of the Aorfix device out to 5 years of follow-up, both overall and within the highly angulated aortic neck group. All-cause mortality and aneurysm-related mortality were similar between groups, and the incidence of sac rupture, type I or type III endoleaks, stent migration, and reintervention was low. Taken together, these data support the use of the Aorfix endograft for EVAR in patients with both standard-angle and highly angulated aortic necks.
The 5-year freedom from all-cause (69%) and aneurysm-related (96%) mortality that we report is consistent with prior randomized controlled EVAR trials. 1, 22, 24, 25 We do not report long-term follow-up of Aorfix vs open AAA repair controls in the current study, but mortality at 2 years was not significantly different between the two groups in our midterm study. 16 There was a slightly higher incidence of all-cause mortality at 5 years in the highly angulated group (33% vs 27%), but this was not statistically significant (P ¼ .43). It is possible this small difference is a reflection of small sample size (ie, type II error) or underlying differences in the patient groups. In addition, patients in the highly angulated neck group were 2.3 years older and more frequently female (35% vs 15%) compared with the low-angle group. Female gender has been identified as an independent risk factor for worse outcomes after EVAR and open aortic aneurysm repair in several large cohort studies in both the short and long term. [26] [27] [28] Given that both overall mortality and EVAR-specific mortality at 5 years in our study are comparable to those in prior reports of EVAR employed predominantly according to other manufacturers' IFU (ie, with aortic neck angle <60 degrees) and in populations with much lower proportions of women than the 29% that we report, the long-term mortality results of the PYTHAGORAS trial are encouraging and support the use of the Aorfix device for patients with highly angulated aortic necks. The 5-year sac expansion rates that we report (12% at 5 years overall) are lower than those of prior studies. In a study of 301 patients undergoing EVAR with the Excluder endograft (W. L. Gore & Associates, Flagstaff, Ariz), sac expansion $5 mm from baseline was noted in 15% of patients at 4 years postoperatively. 29 Similarly, Holt et al reported an 18% primary sac expansion rate after a median follow-up time of 3.6 years among 478 patients undergoing infrarenal EVAR with Zenith (Cook Medical, Bloomington, Ind), Talent (Medtronic, Santa Rosa, Calif), or Endurant (Medtronic) endografts. 24 In a longer term study of the Zenith AAA endograft employed within a Japanese population, sac expansion occurred in 25% of patients at 5 years and in 33% at 10 years. 30 In the latter study, hostile neck anatomy, including preoperative sac diameter and a short angulated proximal neck, was an independent predictor of sac enlargement. 30 Consistent with this notion, we found a trend toward more sac expansion among patients with highly angulated necks in our study. However, the difference was not statistically significant, and this trend did not translate into a higher rate of sac rupture or an increased need for secondary interventions for the highly angulated neck group. As such, the clinical impact of this finding is currently unclear. The high incidence of stent fracture in our study (23% at 5 years) was initially concerning, but nearly all fractures occurred in the barbs and not in the stent itself. Importantly, the fractures were not associated with a correspondingly high rate of stent migration or endoleak, likely because the barb system of the Aorfix is redundant. Before this issue was identified, the method of finishing the nitinol on the stent was modified for manufacturing reasons during the trial. Since that time, many fewer barb fractures have been recorded.
There were also concerns about an increased risk of stent migration among patients with angulated aortic necks based on the midterm PYTHAGORAS outcomes. 16 However, the long-term results that we report do not support this trend. Herein, the risk of Aorfix stent migration at 5 years in patients with highly angulated aortic necks is similar to that in patients with standard neck angulation. Notably, on the basis of experience gained in the PYTHAGORAS trial, the IFU for Aorfix now warn against landing the device >8 mm below the distal renal artery and against implantation in necks that increase in diameter by 5 mm or more over a 15-mm length because nearly all of the migrations observed in this study occurred in these circumstances. We also report no differences in the rate of type I/III or type II endoleaks or need for secondary interventions with the Aorfix among patients with standard-angle vs highly angulated aortic necks. These favorable results are likely due to the flexibility of the graft construction. In a bench study comparing existing aortic endografts, aortic neck angles $30 degrees caused a significant increase in endoleak flow rate in seven manufactured models (Ancure [ 7 In contrast, neck angulation had no influence on the endoleak flow rate of the Aorfix. In a computational model comparing flexibility of the Aorfix with the Zenith stent grafts, the Aorfix graft performed better with respect to maximal luminal reduction rate, torque, strain, and stress for aortic neck angulation >60 degrees. 31 These ex vivo findings, along with the long-term results reported here, support the continued clinical use of Aorfix for EVAR in patients with highly angulated aortic necks. The primary limitation of this study is our lack of randomization. The PYTHAGORAS trial was designed as a nonrandomized regulatory study approved by the U.S. FDA to evaluate the safety and effectiveness of the Lombard Medical Aorfix endograft for the treatment of abdominal aortic, aortoiliac, and common iliac aneurysms with anatomies including angled aorta, angled aneurysmal body, or both, between 0 and 90 degrees. 15 Patients were enrolled in the trial by the on-site investigator, who determined aortic neck angulation and length. Inclusion criteria therefore varied somewhat in these measurements from site to site. However, all aortic neck angulations used for outcome analysis were based on standardized core laboratory measurements, so the anatomic heterogeneity between comparison groups should be minimized. In addition, the baseline demographic, medical comorbidity, and aneurysm characteristics (aside from neck angulation) were similar between groups. There is a possibility that patients with adverse outcomes who died were not captured as aneurysm-related mortality because of lack of rupture or other reasons. However, the likelihood of this possibility is equivalent for both the standard-angle and highly angulated neck groups, so it should not have substantially affected our outcomes. Furthermore, because PYTHAGORAS was designed to test Aorfix efficacy in patients with highly angulated aortic necks, the standard angulation group is likely still composed of a number of patients who would normally have been deemed at high risk for routine endograft placement using an alternative aortic stent graft. As a result, the favorable results presented here in comparison to those of previously published EVAR studies 13, 14, 24, 30 support the safety and efficacy of the Aorfix device in patients with a range of aortic neck angulation.
CONCLUSIONS
The U.S. PYTHAGORAS trial of the Aorfix endograft is the first EVAR clinical trial to include a majority (69%) of highly angulated ($60 degrees) infrarenal aortic necks and is the first to produce evidence after 5 years of implantation. Despite enrolling patients who would be deemed at high risk for EVAR with other endovascular aortic devices because of anatomic limitations, mortality and EVAR-specific outcomes are similar with the Aorfix device compared with other devices treating much less severe anatomy, even when followed up to 5 years. The results presented here are favorable and support the use of this on-label endovascular option, particularly in patients with highly angulated aortic neck anatomy. 
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